Hazel Dockrell

Last updated

Hazel Marguerite [1] Dockrell (born 1952) is an Irish-born microbiologist and immunologist whose research has focused on immunity to the human mycobacterial diseases, leprosy and tuberculosis. She has spent most of her career at the London School of Hygiene and Tropical Medicine, where as of 2020 she is a professor of immunology. She was the first female president of the Royal Society of Tropical Medicine and Hygiene. Jimmy Whitworth of the Wellcome Trust describes her as "a marvellous ambassador for global health and research." [2]

Contents

Early life and education

Dockrell was born in Ireland in 1952 [3] and brought up in Dublin. Her father held medical and dentistry qualifications. She was educated at Alexandra School and College, Dublin, and Trinity College Dublin, where she studied natural sciences, graduating in microbiology. She moved to London for her postgraduate education. Her PhD (1978) was from the Royal Dental Hospital of London (now part of St Thomas' Hospital), researching Sjögren syndrome, a human autoimmune disease; her supervisor was John Greenspan. [2] [4]

Career and research

Her first post-doctoral position was at the immunology department of Middlesex Hospital Medical School (1978–85), working with John Playfair under Ivan Roitt. Her research there was on anti-malarial immune responses. In 1985, she joined the recently established department of clinical tropical medicine at the London School of Hygiene and Tropical Medicine (LSHTM), working with Keith McAdam. Her early research at LSHTM was on immunity to leprosy, particularly the T-cell response to Mycobacterium leprae . She spent time at the Aga Khan University in Karachi where she began a long-term collaboration with the Pakistani immunologist, Rabia Hussain. [2] [4] The clinical presentation of leprosy shows a range of possible symptoms, and Dockrell and Hussain have investigated the way in which the body's anti-mycobacterial immune response determines what form of disease occurs. They have also researched methods to diagnose the disease. [2]

More recently, Dockrell has switched her research focus to tuberculosis, another mycobacterial disease, an area in which she has contributed significant advances. Her work has focused on the immune responses to the bacterium. She has studied the CD8 + T-cell response to mycobacteria, and characterised the profile of biomarkers such as cytokines both to natural infection and to vaccination with the BCG vaccine. In collaboration with the epidemiologist Paul Fine (Karonga Prevention Study, Malawi) and others, she has tried to elucidate why BCG vaccination generates different levels of protection when given in different contexts, such as African countries compared with the UK. [2] [4] She has studied the role in tuberculosis of concurrent infections with helminth parasites as well as non-infectious diseases such as diabetes. She has also promoted global collaborative research into new vaccines against the disease within the European Tuberculosis Vaccine Initiative. [4]

As of 2020, Dockrell is a professor of immunology at LSHTM. [5] In addition to her own research work, Dockrell was the deputy director of research at LSHTM and, as of 2020, advises its director Peter Piot on collaborative programmes with Africa. [2] [5] In the latter role, she has focused on improving the research capabilities of the multiple African institutes with which LSHTM collaborates. [2] Dockrell was the first woman to serve as president of the Royal Society of Tropical Medicine and Hygiene (2009–11). [2] [3]

She has been one of the co-authors of Cedric Mims' textbook Medical Microbiology from the third edition (2003). [6]

Personal life

Her partner is Stephen Gaccon, whom she met while studying for her PhD. [2] [4]

Selected publications

Books
Research papers

Related Research Articles

<span class="mw-page-title-main">BCG vaccine</span> Vaccine primarily used against tuberculosis

The Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). It is named after its inventors Albert Calmette and Camille Guérin. In countries where tuberculosis or leprosy is common, one dose is recommended in healthy babies as soon after birth as possible. In areas where tuberculosis is not common, only children at high risk are typically immunized, while suspected cases of tuberculosis are individually tested for and treated. Adults who do not have tuberculosis and have not been previously immunized, but are frequently exposed, may be immunized, as well. BCG also has some effectiveness against Buruli ulcer infection and other nontuberculous mycobacterial infections. Additionally, it is sometimes used as part of the treatment of bladder cancer.

In biology, immunity is the state of being insusceptible or resistant to a noxious agent or process, especially a pathogen or infectious disease. Immunity may occur naturally or be produced by prior exposure or immunization.

<i>Mycobacterium tuberculosis</i> Species of pathogenic bacteria that causes tuberculosis

Mycobacterium tuberculosis, also known as Koch's bacillus, is a species of pathogenic bacteria in the family Mycobacteriaceae and the causative agent of tuberculosis. First discovered in 1882 by Robert Koch, M. tuberculosis has an unusual, waxy coating on its cell surface primarily due to the presence of mycolic acid. This coating makes the cells impervious to Gram staining, and as a result, M. tuberculosis can appear weakly Gram-positive. Acid-fast stains such as Ziehl–Neelsen, or fluorescent stains such as auramine are used instead to identify M. tuberculosis with a microscope. The physiology of M. tuberculosis is highly aerobic and requires high levels of oxygen. Primarily a pathogen of the mammalian respiratory system, it infects the lungs. The most frequently used diagnostic methods for tuberculosis are the tuberculin skin test, acid-fast stain, culture, and polymerase chain reaction.

<span class="mw-page-title-main">London School of Hygiene & Tropical Medicine</span> UK public research university

The London School of Hygiene & Tropical Medicine (LSHTM) is a public research university in Bloomsbury, central London, and a member institution of the University of London that specialises in public health and tropical medicine. The institution was founded in 1899 by Sir Patrick Manson, after a donation from the Indian Parsi philanthropist B. D. Petit.

Nontuberculous mycobacteria (NTM), also known as environmental mycobacteria, atypical mycobacteria and mycobacteria other than tuberculosis (MOTT), are mycobacteria which do not cause tuberculosis or leprosy/Hansen's disease. NTM are able to cause pulmonary diseases that resemble tuberculosis. Mycobacteriosis is any of these illnesses, usually meant to exclude tuberculosis. They occur in many animals, including humans and are commonly found in soil and water.

<span class="mw-page-title-main">Kiyoshi Shiga</span> Japanese physician (1871–1957)

Kiyoshi Shiga was a Japanese physician and bacteriologist. He had a well-rounded education and career that led to many scientific discoveries. In 1897, Shiga was credited with the discovery and identification of the Shigelladysenteriae microorganism which causes dysentery, and the Shiga toxin which is produced by the bacteria. He conducted research on other diseases such as tuberculosis and trypanosomiasis, and made many advancements in bacteriology and immunology.

Artificial induction of immunity is immunization achieved by human efforts in preventive healthcare, as opposed to natural immunity as produced by organisms' immune systems. It makes people immune to specific diseases by means other than waiting for them to catch the disease. The purpose is to reduce the risk of death and suffering, that is, the disease burden, even when eradication of the disease is not possible. Vaccination is the chief type of such immunization, greatly reducing the burden of vaccine-preventable diseases.

Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. As of 2021, the only effective tuberculosis vaccine in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on humans in 1921. It consists of attenuated (weakened) strains of the cattle tuberculosis bacillus. It is recommended for babies in countries where tuberculosis is common.

rBCG30 is a prospective Bacillus Calmette-Guérin vaccine against tuberculosis. It is a live vaccine, consisting of BCG, which has been evaluated as a tuberculosis vaccination. It is genetically modified to produce abundant amounts of mycolyl transferase, a 30kDa antigen that has been shown to produce a strong immune response in animals and humans. rBCG30 had been in human clinical trials, but no clinical development has been reported since 2007.

<span class="mw-page-title-main">Ruth Arnon</span> Israeli biochemist

Ruth Arnon is an Israeli biochemist and codeveloper of the multiple sclerosis drug Copaxone. She is currently the Paul Ehrlich Professor of Immunology at the Weizmann Institute of Science, where she is researching anti-cancer and influenza vaccinations.

An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable. Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the pathogen.

Interferon-gamma release assays (IGRAs) are diagnostic tools for latent tuberculosis infection (LTBI). They are surrogate markers of Mycobacterium tuberculosis infection and indicate a cellular immune response to M. tuberculosis if the latter is present.

Polly Roy OBE is a professor and Chair of Virology at The London School of Hygiene and Tropical Medicine. She attended a number of schools which included Columbia University Medical School, Rutgers University, University of Alabama, and University of Oxford. In 2001 she became a part of The London School of Hygiene and Tropical Medicine and, along with being the chair of Virology, is also the co-organiser of the medical microbiology course. The virus that she has dedicated most of her career to is Bluetongue disease that affects sheep and cattle. She became interested in this virus after attending a symposium and was intrigued by the fact that not much was known about the virus that was causing such a nasty and sometimes fatal disease.

<span class="mw-page-title-main">Lalita Ramakrishnan</span> Indian-American microbiologist

Lalita Ramakrishnan is an Indian-born American microbiologist who is known for her contributions to the understanding of the biological mechanism of tuberculosis. As of 2019 she serves as a professor of Immunology and Infectious Diseases at the University of Cambridge, where she is also a Wellcome Trust Principal Research Fellow and a practicing physician. Her research is conducted at the MRC Laboratory of Molecular Biology, where she serves as the Head of the Molecular Immunity Unit of the Department of Medicine embedded at the MRC LMB. Working with Stanley Falkow at Stanford, she developed the strategy of using Mycobacterium marinum infection as a model for tuberculosis. Her work has appeared in a number of journals, including Science, Nature, and Cell. In 2018 and 2019 Ramakrishnan coauthored two influential papers in the British Medical Journal (BMJ) arguing that the widely accepted estimates of the prevalence of latent tuberculosis—estimates used as a basis for allocation of research funds—are far too high. She is married to Mark Troll, a physical chemist.

Elizabeth Lucy Corbett is a British epidemiologist who is Professor of Tropical Epidemiology at the London School of Hygiene & Tropical Medicine. Her research investigates the regulation of tuberculosis in HIV prevalent populations and improving access to HIV self-testing.

Marylyn Martina Addo is a German infectiologist who is a Professor and the German Center for Infection Research (DZIF) Head of Infectious Disease at the University Medical Center Hamburg-Eppendorf. Addo has developed and tested vaccinations that protect people from Ebola virus disease and the MERS coronavirus EMC/2012. She is currently developing a viral vector based COVID-19 vaccine.

MTBVAC is a candidate vaccine against tuberculosis in humans currently in research trials. It is based on a genetically modified form of the Mycobacterium tuberculosis pathogen isolated from humans.

<span class="mw-page-title-main">Susanna Dunachie</span> British microbiologist

Susanna Jane Dunachie is a British microbiologist who is Professor of Infectious Diseases at the University of Oxford. Her work considers microbiology and immunology to better understand bacterial infection and accelerate the development of vaccines. She has focused on melioidosis, scrub typhus and tuberculosis. During the COVID-19 pandemic, she studied T cell immunity to severe acute respiratory syndrome coronavirus 2.

Shabaana A. Khader is an Indian-American microbiologist who is the Bernard and Betty Roizman Professor of Microbiology at the University of Chicago. She is also the Chair of the Department of Microbiology. In an effort to design new vaccines and therapeutic strategies, Khader studies host-pathogen interactions in infectious disease.

References

  1. ↑ Hazel Marguerite Dockrell, UK Research and Innovation , retrieved 15 February 2020
  2. 1 2 3 4 5 6 7 8 9 Morris, Kelly (2012), "Hazel Dockrell: Ambassador for international health research", The Lancet , 379 (9812): 211, doi:10.1016/S0140-6736(12)60090-7, PMID   22265620, S2CID   205964985
  3. 1 2 Hay, S. I.; McHugh, G. M. (2013), "Presidential addresses of the Royal Society of Tropical Medicine and Hygiene: 1907–2013", Transactions of the Royal Society of Tropical Medicine and Hygiene , 107 (10): 603–07, doi:10.1093/trstmh/trt066, PMC   3892027 , PMID   24026462
  4. 1 2 3 4 5 Dockrell, H. M. (2017), "Working together toward vaccines and biomarkers in the real world", Human Vaccines & Immunotherapeutics , 13 (7): 1492–94, doi:10.1080/21645515.2017.1322443, PMC   5512766 , PMID   28574742
  5. 1 2 Professor Hazel Dockrell: BA PhD: Professor of Immunology, Special Advisor on Overseas Partnerships in Africa, London School of Hygiene and Tropical Medicine , retrieved 15 February 2020
  6. ↑ Cedric Mims; Hazel Dockrell; Richard Goering; Ivan Roitt; Derek Wakelin; Mark Zuckerman (2003), Medical Microbiology (3rd ed.), Mosby, ISBN   978-0-7234-3259-3
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.